Vaccinex, Inc. (VCNX)
Total Valuation
Vaccinex has a market cap or net worth of $8.69 million. The enterprise value is $8.87 million.
Market Cap | 8.69M |
Enterprise Value | 8.87M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
Earnings Date | May 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Vaccinex has 1.17 million shares outstanding. The number of shares has increased by 58.45% in one year.
Shares Outstanding | 1.17M |
Shares Change (YoY) | +58.45% |
Shares Change (QoQ) | +11.89% |
Owned by Insiders (%) | 9.18% |
Owned by Institutions (%) | 56.64% |
Float | 326,297 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 10.93 |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 11.16 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.35
Current Ratio | 0.35 |
Quick Ratio | 0.17 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,667.30%.
Return on Equity (ROE) | -2,667.30% |
Return on Assets (ROA) | -475.50% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | $20,921 |
Profits Per Employee | -$579,263 |
Employee Count | 38 |
Asset Turnover | 0.17 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.84% in the last 52 weeks. The beta is 0.76, so Vaccinex's price volatility has been lower than the market average.
Beta (1Y) | 0.76 |
52-Week Price Change | -90.84% |
50-Day Moving Average | 8.58 |
200-Day Moving Average | 27.59 |
Relative Strength Index (RSI) | 38.76 |
Average Volume (30 Days) | 11,528 |
Short Selling Information
The latest short interest is 8,792, so 0.75% of the outstanding shares have been sold short.
Short Interest | 8,792 |
Short Previous Month | 14,828 |
Short % of Shares Out | 0.75% |
Short % of Float | 2.69% |
Short Ratio (days to cover) | 0.44 |
Income Statement
In the last 12 months, Vaccinex had revenue of $795,000 and -$22.01 million in losses. Loss per share was -$84.56.
Revenue | 795,000 |
Gross Profit | 795,000 |
Operating Income | -23.02M |
Pretax Income | -22.01M |
Net Income | -22.01M |
EBITDA | -21.88M |
EBIT | -22.01M |
Loss Per Share | -$84.56 |
Balance Sheet
The company has $127,000 in cash and $307,000 in debt, giving a net cash position of -$180,000 or -$0.15 per share.
Cash & Cash Equivalents | 127,000 |
Total Debt | 307,000 |
Net Cash | -180,000 |
Net Cash Per Share | -$0.15 |
Equity / Book Value | -3.87M |
Book Value Per Share | -3.32 |
Working Capital | -4.16M |
Cash Flow
In the last 12 months, operating cash flow was -$18.24 million and capital expenditures -$65,000, giving a free cash flow of -$18.31 million.
Operating Cash Flow | -18.24M |
Capital Expenditures | -65,000 |
Free Cash Flow | -18.31M |
FCF Per Share | -$56.87 |
Margins
Gross margin is 100.00%, with operating and profit margins of -2,895.09% and -2,768.81%.
Gross Margin | 100.00% |
Operating Margin | -2,895.09% |
Pretax Margin | -2,768.81% |
Profit Margin | -2,768.81% |
EBITDA Margin | -2,751.57% |
EBIT Margin | -2,768.81% |
FCF Margin | -2,302.64% |
Dividends & Yields
Vaccinex does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -58.45% |
Shareholder Yield | -58.45% |
Earnings Yield | -253.26% |
FCF Yield | -210.62% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 20, 2024. It was a reverse split with a ratio of 1:14.
Last Split Date | Feb 20, 2024 |
Split Type | Reverse |
Split Ratio | 1:14 |
Scores
Vaccinex has an Altman Z-Score of -213.45 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -213.45 |
Piotroski F-Score | 3 |